Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 1/2008

01.01.2008 | Review Article

Cost-Effectiveness Analyses of Hepatitis A Vaccine

A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies

verfasst von: Andrea M. Anonychuk, Andrea C. Tricco, Chris T. Bauch, Ba’ Pham, Vladimir Gilca, Bernard Duval, Ava John-Baptiste, Gloria Woo, Dr Murray Krahn

Erschienen in: PharmacoEconomics | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Cost-effectiveness/cost-utility studies of hepatitis A vaccine were identified via a series of literature searches (MEDLINE, EMBASE, HSTAR and SSCI). Citations and full-text articles were reviewed independently by two reviewers. Reference searching, author searches and expert consultation ensured literature saturation. Incremental cost-effectiveness ratios (ICERs) were abstracted for base-case analyses, converted to $US, year 2005 values, and categorised to reflect various levels of cost effectiveness. Quality of reporting, methodological issues and key modelling issues were assessed using frameworks published in the literature.
Thirty-one cost-effectiveness studies (including 12 cost-utility analyses) were included from full-text article review (n = 58) and citation screening (n = 570). These studies evaluated universal mass vaccination (n = 14), targeted vaccination (n = 17) and vaccination of susceptibles (i.e. individuals initially screened for antibody and, if susceptible, vaccinated) [n = 13]. For universal vaccination, 50% of the ICERs were <$US20 000 per QALY or life-year gained. Analyses evaluating vaccination in children, particularly in high incidence areas, produced the most attractive ICERs. For targeted vaccination, cost effectiveness was highly dependent on the risk of infection.
Incidence, vaccine cost and discount rate were the most influential parameters in sensitivity analyses. Overall, analyses that evaluated the combined hepatitis A/hepatitis B vaccine, adjusted incidence for under-reporting, included societal costs and that came from studies of higher methodological quality tended to have more attractive cost-effectiveness ratios. Methodological quality varied across studies. Major methodological flaws included inappropriate model type, comparator, incidence estimate and inclusion/exclusion of costs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Di Giammarino L, Dienstag JL. Hepatitis A: the price of progress. N Engl J Med 2005 Sep 1; 353 (9): 944–946CrossRef
2.
Scheifele DW, Ochnio J. Hepatitis A vaccine: is it being used to best advantage? CMAJ 2002 Jul 9; 167 (1): 44–45PubMed
3.
Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005 Jul 13; 294 (2): 202–210PubMedCrossRef
4.
Dominguez A, Bruguera M, Plans P, et al. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization. J Med Virol 2004 Jun; 73 (2): 172–176PubMedCrossRef
5.
Germinario C, Lopalco PL, Chirona M, et al. Fromhepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 2000 Feb 18; 18 Suppl. 1: S83–S85PubMedCrossRef
6.
Jenson HB. The changing picture of hepatitis A in the United States. Curr Opin Pediatr 2004 Feb; 16 (1): 89–93PubMedCrossRef
7.
Navas E, Salleras L, Gisbert R, et al. Efficiency of the incorporation of the hepatitis a vaccine as a combined A + B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine 2005; 23 (17–18): 2185–2189PubMedCrossRef
8.
Health Canada. Canadian immunization guide. 6th ed. Ottawa: Canadian Medical Association, 2002
9.
Andre FE. Universal mass vaccination against hepatitis A. Curr Top Microbiol Immunol 2006; 304: 95–114PubMedCrossRef
10.
Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101–111PubMedCrossRef
11.
12.
Mason J, Eccles M, Freemantle N, et al. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy 1999; 47 (1): 37–52PubMedCrossRef
13.
Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329 (7459): 224–227PubMedCrossRef
14.
Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20 (1): 1–7PubMedCrossRef
15.
Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med 2000 Jun 20; 132 (12): 964–972PubMed
16.
Davies L, Coyle D, Drummond M. Current status of economic appraisal of health technology in the European Community: report of the network. The EC Network on the Methodology of Economic Appraisal of Health Technology. Soc Sci Med 1994; 38 (12): 1601–1607PubMedCrossRef
17.
Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the UK. Soc Sci Med 1997; 45 (4): 583–595PubMedCrossRef
18.
Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999 Dec 15; 18 (23): 3263–3282PubMedCrossRef
19.
Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003 Jan; 23 (1): 76–82PubMedCrossRef
20.
Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 2004 Oct; 22 (31–32): 4342–4350PubMedCrossRef
21.
Chen H, Bauch C, Foty R, et al. Use of catalytic modeling to estimate hepatitis A incidence in a low endemicity country: implications for modeling immunization policies [abstract]. Available from URL: http://​smdm.​confex.​com/​smdm/​2004ga/​ techprogram/P1609.htm [Accessed 2007 Oct 31]
22.
Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002 May; 109 (5): 839–845PubMedCrossRef
23.
Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar 25; 332 (7543): 699–703PubMedCrossRef
24.
Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977 Jun; 33 (2): 363–374PubMedCrossRef
25.
26.
US Department of Labor. US labor statistics data [online]. Available from URL: http://​data.​bls.​gov/​PDQ/​servlet/​SurveyOutputServ​let [Accessed 2007 Jan 1]
27.
Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004 Feb; 7 (1): 43–49PubMedCrossRef
28.
Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 Feb 15; 146 (4): 473–481PubMed
29.
Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998 Oct; 13 (10): 716–717PubMedCrossRef
30.
Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355–371PubMedCrossRef
31.
Arguedas MR, Heudebert GR, Fallon MB, et al. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002 Mar; 97 (3): 721–728PubMedCrossRef
32.
Arnal JM, Frisa O, Garuz R, et al. Cost effectiveness of hepatitis A virus immunisation in Spain. Pharmacoeconomics 1997; (3): 361–373CrossRef
33.
Bauch CT, Anonychuk AM, Pham BZ, et al. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007; 25 (51): 8536–8548PubMedCrossRef
34.
Buma AH, Beutels P, Van DP, et al. An economic evaluation of hepatitis A vaccination in Dutch military personnel. Mil Med 1998 Aug; 163 (8): 564–567PubMed
35.
Chodick G, Lerman Y, Wood F, et al. Cost-utility analysis of hepatitis a prevention among health-care workers in Israel. J Occup Environ Med 2002; 44 (2): 109–115PubMedCrossRef
36.
Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 1999; (2): 548–552CrossRef
37.
Demicheli V, Carniglia E, Fucci S. The use of hepatitis A vaccination in Italy: an economic evaluation. Vaccine 2003 Jun 2; 21 (19-20): 2250–2257PubMedCrossRef
38.
Diel R, Rappenhoner B, Schneider S. Cost-effectiveness of hepatitis A immunization of children and adolescents in Germany. Hepac Health Econ Prev Care 2001; 2 (3): 96–103CrossRef
39.
Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Ped Adolesc Med 2000; 154 (8): 763–770
40.
Jacobs RJ, Grover SF, Meyerhoff AS, et al. Cost effectiveness of vaccinating food service workers against hepatitis A infection. J Food Protect 2000 Jun; 63 (6): 768–774
41.
Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97 (2): 427–434PubMed
42.
Jacobs RJ, Greenberg DP, Koff RS, et al. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003; 22 (10): 904–914PubMedCrossRef
43.
Jacobs RJ, Meyerhoff AS. Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics. Sex Transm Dis 2003 Nov; 30 (11): 859–865PubMedCrossRef
44.
Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003 May; 51 (6): 227–236PubMedCrossRef
45.
Jacobs RJ, Gibson GA, Meyerhoff AS. Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the Western United States. Infect Control Hosp Epidemiol 2004; 25 (7): 563–569PubMedCrossRef
46.
Jacobs RJ, Rosenthal P, Meyerhoff AS. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates. Vaccine 2004 Mar 12; 22 (9–10): 1241–1248PubMedCrossRef
47.
Jefferson TO, Behrens RH, Demicheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine 1994; 12 (15): 1379–1383PubMedCrossRef
48.
Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000; 31 (4): 834–839PubMedCrossRef
49.
O’Connor JB, Imperial ’ TF, Singer ME. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 1999; 30 (4): 1077–1081PubMedCrossRef
50.
Pechevis M, Khoshnood B, Buteau L, et al. Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection. Vaccine 2003; 21 (25–26): 3556–3564PubMedCrossRef
51.
Postma MJ, Bos JM, Beutels P, et al. Pharmacoeconomic evaluation of targeted hepatitis a vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 2004; 22 (15–16): 1862–1867PubMedCrossRef
52.
Raj an E, Shattock AG, Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland. Am J Gastroenterol 2000; 95 (1): 223–226CrossRef
53.
Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007 Jan; 119 (1): el2–el21CrossRef
54.
Severo CA, Fagnani F, Lafuma A. Cost effectiveness of hepatitis A prevention in France. Pharmacoeconomics 1995; 8 (1): 46–61PubMedCrossRef
55.
Smith S, Weber S, Wiblin T, et al. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect Control Hosp Epidemiol 1997 Oct; 18 (10): 688–691PubMedCrossRef
56.
Szucs T. Cost-effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine 2000; 18 (SI): S86–S89PubMedCrossRef
57.
Tormans G, Van DP, Van DE. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine 1992; 10 (SI): S88–S92PubMedCrossRef
58.
Valenzuela MT, Jacobs RJ, Arteaga O, et al. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005; 23 (32): 4110–4119PubMedCrossRef
59.
Van Doorslaer E, Tormans G, Van DP. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J Med Virol 1994; 44 (4): 463–469PubMedCrossRef
60.
Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg 1985 Jun; 94 (3): 365–436CrossRef
61.
Ukkonen P, von Bonsdorff CH. Rubella immunity and morbidity: effects of vaccination in Finland. Scand J Infect Dis 1988; 20 (3): 255–259PubMedCrossRef
62.
Muench H. Catalytic models in epidemiology. Cambridge (MA): Harvard University Press, 1959
63.
Mutsch M, Spicher VM, Gut C, et al. Hepatitis infection in travellers 1988–2004. Clin Infect Dis 2006 Feb 15; 42 (4): 490–497PubMedCrossRef
64.
Berge JJ, Drennan DP, Jacobs RJ, et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000 Feb; 31 (2): 469–473PubMedCrossRef
65.
Anonychuk A, Krahn M, Gilca V, et al. The cost of hepatitis A in Canada: ministry and societal perspectives [abstract]. Society for Medical Decision Making Conference; 2006 Oct 14–18; Boston [online]. Available from URL: http://​smdm.​c onfex.com/smdm/2006ma/techprogram/P3122.htm [Accessed 2007 Oct 1]
66.
Triceo AC, Pham B, Duval B, et al. A review of interventions triggered by hepatitis A infected food-handlers in Canada. BMC Health Serv Res 2006; 6: 157CrossRef
67.
Dalton CB, Haddix A, Hoffman RE, et al. The cost of a food-borne outbreak of hepatitis A in Denver, Colo. Arch Intern Med 1996 May 13; 156 (9): 1013–1016PubMedCrossRef
68.
Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
69.
Weinstein MC, Siegel IE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996 Oct 16; 276 (15): 1253–1258PubMedCrossRef
70.
Song F, Eastwood AJ, Gilbody S, et al. Publication and related biases. Health Technol Assess 2000; 4: 1–115
71.
Dickersin K. Publication bias: recognizing the problem, understanding its origins and scope, and preventing harm. In: Rothstein H, Sutton AJ, Borenstein M, editors. Publication bias in meta-analysis: prevention, assessment and adjustments. Chichester: John Wiley & Sons Ltd, 2005
72.
Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 2000; 263: 1385–1389CrossRef
Metadaten
Titel
Cost-Effectiveness Analyses of Hepatitis A Vaccine
A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies
verfasst von
Andrea M. Anonychuk
Andrea C. Tricco
Chris T. Bauch
Ba’ Pham
Vladimir Gilca
Bernard Duval
Ava John-Baptiste
Gloria Woo
Dr Murray Krahn
Publikationsdatum
01.01.2008
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 1/2008
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200826010-00003

Weitere Artikel der Ausgabe 1/2008

PharmacoEconomics 1/2008 Zur Ausgabe

Original Research Article

Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections

Editorial

The New Myth

Original Research Article

Dynamic Modelling of Infectious Diseases

Review Article

The Last Decade of Italian Pharmaceutical Policy

Original Research Article

Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration

Original Research Article

Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas